RESEARCH COMMUNICATION

Precise temporal control of the eye regulatory gene *Pax6* via enhancer-binding site affinity

Sheldon Rowan,^{1,4} Trevor Siggers,^{1,4} Salil A. Lachke,¹ Yingzi Yue,¹ Martha L. Bulyk,^{1,2,3,5} and Richard L. Maas^{1,6}

¹Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA; ²Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA; ³Harvard-Massachusetts Institute of Technology Division of Health Sciences and Technology (HST), Harvard Medical School, Boston, Massachusetts 02115, USA

How transcription factors interpret the *cis*-regulatory logic encoded within enhancers to mediate quantitative changes in spatiotemporally restricted expression patterns during animal development is not well understood. *Pax6* is a dosage-sensitive gene essential for eye development. Here, we identify the Prep1 (pKnox1) transcription factor as a critical dose-dependent upstream regulator of *Pax6* expression during lens formation. We show that Prep1 activates the *Pax6* lens enhancer by binding to two phylogenetically conserved lower-affinity DNA-binding sites. Finally, we describe a mechanism whereby *Pax6* levels are determined by transcriptional synergy of Prep1 bound to the two sites, while timing of enhancer activation is determined by binding site affinity.

Supplemental material is available at <http://www.genesdev.org>.

Received November 24, 2009; revised version accepted March 17, 2010.

The precise spatiotemporal patterns of metazoan gene expression are controlled by *cis*-regulatory modules (CRMs), which are regions of DNA, typically a few hundred base pairs long, that comprise binding sites for transcriptional regulators (Yuh et al. 1998; Arnosti and Kulkarni 2005; Davidson and Levine 2008). While current genomic approaches have traditionally focused on identifying the highest-affinity transcription factor (TF)-binding sites, new genome-wide location analyses have demonstrated widespread TF binding in the absence of high-affinity sites, thus forcing a re-evaluation of the scope and regulatory significance of lower-affinity sites (Hollenhorst et al. 2007; Gordan et al. 2009).

[**Keywords:** Transcription factor; protein-binding microarray; DNA-binding site affinity; eye development; mathematical modeling; gene regulation]

⁴These authors contributed equally to this work.

Corresponding authors.

⁵E-MAIL mlbulyk@receptor.med.harvard.edu; FAX (617) 525-4705.

⁶E-MAIL maas@genetics.med.harvard.edu; FAX (617) 525-4751.

Article published online ahead of print. Article and publication date are online at <http://www.genesdev.org/cgi/doi/10.1101/gad.1890410>.

The affinity of a binding site provides a mechanism to respond to different concentrations of TFs. In development, the ability of CRMs that contain sites of differing affinities to interpret TF gradients has been studied in *Drosophila melanogaster* and other organisms for spatial gradients (Driever et al. 1989; Struhl et al. 1989; Jiang and Levine 1993; Scardigli et al. 2003; Segal et al. 2008), and in *Caenorhabditis elegans* and sea urchin for temporal gradients (Lai et al. 1988; Gaudet and Mango 2002). For example, in *C. elegans*, altering PHA-4 DNA-binding sites to higher- or lower-affinity sequences altered the onset of pharyngeal gene expression, with higher-affinity sites directing expression earlier in development (Gaudet and Mango 2002). The ability to tune the timing of expression by modulating the affinity of the DNA-binding site(s) for just one TF is conceptually appealing. However, it remains unclear whether such a simple mechanism could operate in the context of a complex vertebrate developmental enhancer.

Pax6 is a key regulator of metazoan eye development, and in mammals is required in a dose-dependent fashion for lens induction and specification (Hill et al. 1991; Grindley et al. 1995; Ashery-Padan et al. 2000; van Raamsdonk and Tilghman 2000; Davis-Silberman et al. 2005). Furthermore, the precise *cis* regulation of *Pax6* is obligatory, as alteration in either the timing or level of *Pax6* expression has profound effects on eye development (Schedl et al. 1996; van Raamsdonk and Tilghman 2000; Duncan et al. 2004). Several groups have molecularly dissected regulatory elements contained within a region of *Pax6* that contains the P0 promoter and 3.9 kb of upstream sequence (P0-3.9), and identified CRMs that control expression in the lens (denoted as the *Pax6* ectodermal enhancer or EE) and endocrine pancreas (Williams et al. 1998; Kammandel et al. 1999; Zhang et al. 2002, 2006). Within the EE, there is a highly conserved minimal 104-base-pair (bp) region sufficient to direct lens-specific expression (Williams et al. 1998), and several TFs—including Sox2, Oct1 (Pou2f1), Meis1/2, and *Pax6* itself—have been shown to bind this region (Zhang et al. 2002; Aota et al. 2003; Donner et al. 2007). Here we decode a *cis*-regulatory logic whereby DNA-binding site affinities of a novel EE regulator, Prep1, are used to control the timing of *Pax6* activation in the developing lens.

Results and Discussion

Prep1 (also known as Pknox1) is a homeobox TF in the TALE superfamily that was identified previously along with other closely related Meis TFs as a regulator of the *Pax6* pancreatic enhancer (Zhang et al. 2006). *Prep1* homozygous-null mouse embryos (*Prep1*^{−/−}) do not survive to midgestation, while *Prep1* hypomorphs, where RNA expression is reduced to ~2% of wild-type levels due to a retroviral insertion in first intron of *Prep1* (*Prep1*^{1/1}), show highly variable phenotypes (Ferretti et al. 2006). We found that *Prep1* trans-heterozygotes (*Prep1*^{1/−}) generally survive until embryonic days 12.5–14.5 (E12.5–E14.5), and exhibit distinct and highly penetrant phenotypes (Fig. 1A; Supplemental Table 1). Strikingly, *Prep1*^{1/−} mutants lack an external eye, with an arrest in eye development by E10.5 (Fig. 1A), the same

Figure 1. Genetic requirement for *Prep1* in lens induction. (A) Whole-mount control or *Prep1*^{−/−} mutants at E10.5, E12.5, and E14.5. The inset shows high magnification of eye region (boxed). Arrows show the absence of eyes. (B) Sections through E12.5 control or *Prep1*^{−/−} mutant eyes stained with hematoxylin and eosin to show histology, or stained with antibodies to Foxe3, γ -crystallin, or Pax6 as indicated. (C) Sections through E9.5 or E10.5 control or *Prep1*^{−/−} mutant embryos stained with antibodies for Pax6 or Foxe3. Arrows indicate presumptive lens ectoderm, and arrowheads indicate non-lens head ectoderm. Bars: B,C, 100 μ m. (l) Lens; (r) retina.

time point at which eye development arrests in *Pax6* mutant mice.

Histological analysis at E12.5 revealed an absence of lens tissue, and marker analyses revealed that neither lens epithelial cells (Foxe3⁺), nor lens fiber cells (γ -crystallin⁺), nor lens precursor cells (Pax6⁺) formed (Fig. 1B). Foxe3 is a dose-dependent Pax6 target gene in the presumptive lens epithelium (Fig. 1C) and a definitive marker of lens specification (Blixt et al. 2007). *Prep1*^{−/−} mutant mice do not initiate Foxe3 expression (Fig. 1C), and while Pax6 is initially expressed in the presumptive lens epithelium of *Prep1*^{−/−} mutants, its expression is subsequently lost specifically in the lens preplacode, which fails to thicken or invaginate at E10.5 to form the lens placode (Fig. 1C). Conversely, *Prep1* is coexpressed with Pax6 in the presumptive lens epithelium, and does not depend on Pax6 for its expression (Supplemental Figs. 1, 2). These data

identify *Prep1* as a novel regulator of lens induction, and also as a putative regulator of *Pax6* expression.

Pax6 regulation during lens development is complex, with multiple enhancers controlling the earliest phase of expression in lens preplacodal epithelium, and the *Pax6* EE having a more significant role later during lens induction (Williams et al. 1998; Dimanlig et al. 2001). We evaluated whether *Pax6* regulatory elements might be regulated directly by *Prep1* by crossing a P0-3.9 *Pax6* reporter transgene (Fig. 2C; Rowan et al. 2008) into the *Prep1*^{−/−} mutant background. Strikingly, the activity of this GFP reporter in the eye was reduced dramatically in E10.0 *Prep1*^{−/−} mutants, while pancreatic enhancer activity was unaltered (Fig. 2A). The expression of other TFs that reside upstream of the *Pax6* EE was retained in *Prep1*^{−/−} mutants, ruling out indirect regulation via these factors (Supplemental Fig. 3).

We sought to determine whether the P0-3.9 region contained potential *Prep1*-binding sites. To search the P0-3.9 region for potential *Prep1*-binding sites, we used protein-binding microarray (PBM) data on *Prep1* (Berger et al. 2008), which provide comprehensive and quantitative in vitro assessment of binding to all possible 8-bp DNA sequences. Along with a previously identified binding site in the *Pax6* P0-3.9 region that is required for *Pax6* pancreatic enhancer activity (denoted P1) (Zhang et al. 2006), we identified several lower-scoring putative binding sites throughout the region, including a pair of sites in the EE (denoted L1, L2) that are separated from each other by 34 bp (Fig. 2B,C). The high-scoring P1 sequence was a perfect match to the *Prep1* DNA-binding site motif (Berger et al. 2008), while L1 and L2 each had a single phylogenetically conserved mismatch (L1: TTGTCA; L2: CTGTCT) from the optimal core 6-bp sequence 5'-CTGTCA-3' (Fig. 2B,C). The single base mismatches in the L1 and L2 sites are consistent with the PBM data, indicating that L1 and L2 are lower-affinity *Prep1*-binding sites.

Motivated by the PBM data, we used surface plasmon resonance (SPR) to quantitatively measure the binding affinity of *Prep1* to genomic sequences encompassing the L1, L2, and P1 sites (Majka and Speck 2007). P1 is a high-affinity *Prep1*-binding site, with a dissociation constant (K_d) of 14 $\pm$ 3.4 nM (mean $\pm$ SD), whereas L1 and L2 are of approximately sixfold to sevenfold lower affinity, with K_d values of 106 $\pm$ 4.3 and 92 $\pm$ 16 nM, respectively (Fig. 3A,B). These relative affinity differences agree well with estimates derived independently from the PBM data (Fig. 3B). Searching for *Prep1*-binding sites in multiple aligned genomes, we found two lower-scoring sites, spaced 34 bp apart, aligning to L1 and L2 (Fig. 2C; Supplemental Fig. 4) throughout the vertebrate lineage, suggesting conservation of affinity and function.

The L1 site was previously mutated and shown to be essential for EE activity (Zhang et al. 2002); hence, we sought to test the functional significance of the L2 site for EE regulation. *Pax6* P0-3.9 reporters containing an ablation of the L2 site resulted in loss of reporter activity in the developing lens (Fig. 3C). Additional reporter analyses indicated that L1 and L2 function nonredundantly as critical *Pax6* regulators (Fig. 3C). These results suggested three possible models: (1) *Prep1* binds cooperatively to the two sites, but when either site is mutated, it is insufficiently bound to activate detectable levels of expression. (2) *Prep1* binds independently to each site, with

Figure 2. Prep1 is required for *Pax6* EE activation and binds multiple highly conserved sites upstream of *Pax6*. (A) Whole-mount GFP visualization of E10 control or *Prep1*^{-/-} mutant eyes expressing the *P0-3.9-GFP-Cre* transgene, or section through the pancreas of the same embryo stained with antibodies for Pdx1 and GFP. Dotted line marks the optic vesicle. (B) Logo of the Prep1 DNA-binding site motif (Berger et al. 2008), with a box showing the CTGTCA core sequence. (C) Schematic of the *Pax6* P0-3.9 genomic region used in the transgenic mouse line. P0 box represents the location of the *Pax6* P0 promoter. Shown in the University of California at Santa Cruz Genome Browser view are PBM scores (enrichment score, ≥ 0.37) from a sliding 8-bp window. Hits in the minimal essential region of the EE (cyan) or Pancreas enhancer (magenta) are labeled L1, L2, and P1; sequences are shown boxed below. Red nucleotides indicate divergence from the boxed CTGTCA core sequence.

DNA-bound Prep1 proteins acting synergistically to activate detectable levels of transcripts. (3) Individual DNA-bound Prep1 proteins cannot activate expression, and binding to both sites is required to form a larger, multi-component complex required for *Pax6* expression.

We used SPR to measure the binding of full-length Prep1 to a DNA probe containing the portion of the EE spanning the L1 and L2 sites in the event that regions outside the DNA-binding domain may mediate cooperative protein interactions. We did not detect any cooperative binding (Supplemental Fig. 5), arguing against model 1. Model 2 proposes synergistically acting lower-affinity sites. We reasoned that our mutant reporter constructs ($\Delta L1L2$ and $L1\Delta L2$) might be rescued by substituting the remaining, native lower-affinity site in each of the constructs with a high-affinity site resembling the P1 site ($\Delta L1L2^*$ and $L1^*\Delta L2$). Strikingly, both constructs rescued EE reporter activity, but only to a modest extent and only in a minority of transgenic embryos, while expression from an $L1L2$ to $L2L1$ swap or from the $L1^*L2^*$ double-mutant construct was not significantly different from that of $L1L2$ (Fig. 4A). These results demonstrate several important features of the EE element: (1) Prep1 occupancy at either site under native conditions is below saturation. (2) Prep1 bound to either L1 or L2 sites can provide the necessary requirements for activation (thereby ruling out model 3). (3) Prep1 molecules bound to L1 and L2 act synergistically and without a preferred order relative to each other to achieve wild-type EE expression levels.

We employed a biophysical model (Bintu et al. 2005) of the *Pax6* EE to investigate whether a model based on transcriptional synergy between Prep1 bound independently to the L1 and L2 sites could explain the behavior of our reporter constructs and provide further testable predictions. Expression was modeled as equilibrium binding of Prep1, with DNA-bound Prep1 recruiting a required

cofactor (e.g., TFIID) or RNA polymerase II. The model was parameterized directly by using our SPR-determined binding affinities, and indirectly by requiring consistency with relative expression levels from our reporter constructs. In the absence of Prep1-binding cooperativity, we find that synergistic activation is required by Prep1 bound at L1 and L2 in order to achieve agreement with the experimental reporter expression data (Fig. 4B,C). The levels of Prep1 protein that are consistent with the relative reporter expression data lie in a narrow range (Fig. 4C, shaded region) that is consistent with published nuclear TF concentrations (Gregor et al. 2007; Giorgetti et al. 2010). For this range of Prep1 concentrations, the model predicts that the EE should be highly sensitive to Prep1 levels. This prediction is consistent with the dramatically reduced EE activity observed in *Prep1*^{-/-} mutant mice (Fig. 2A).

In light of the model, we re-examined why both Prep1-binding sites are highly conserved as lower-affinity sites, given that substitution of both sites for high-affinity versions ($L1^*L2^*$) did not alter reporter activity at E10.5. We found that, at concentrations of Prep1 below those modeled for E10.5, the predicted difference in expression between the $L1^*L2^*$ and $L1L2$ constructs is enhanced (Supplemental Figs. 6, 7). Prep1 mRNA and protein levels are known to increase during early mouse development (Ferretti et al. 1999), as does EE activity (Williams et al. 1998). We predicted, therefore, that the $L1^*L2^*$ construct should be expressed at higher levels than $L1L2$ at stages preceding E10.5, when Prep1 levels are lower (see Supplemental Figs. 1, 2). We tested this prediction, and indeed found that $L1^*L2^*$ directed inappropriately high reporter activity at E9.5 (Fig. 4D). Our interpretation, therefore, is that Prep1-binding site affinity provides a mechanism for controlling the timing of *Pax6* expression in lens development. Additionally, we detected specific regions of expanded reporter activity in

Figure 3. L1 and L2 are essential lower-affinity Prep1-binding sites. (A) SPR dose response curves for GST-Prep1 on L1, L2, or P1. (B) Kd values of Prep1 for L1-, L2-, and P1-binding sites and fold change in affinity relative to the P1 site (numbers >1 indicate decreased affinity) as determined by SPR and PBM data. (C) Whole-mount view of β -galactosidase-stained E10.5 embryos expressing wild-type *P0-3.9-L1L2* or *P0-3.9-L1 Δ L2* transgenes. The arrow points to the lens, while the arrowhead points to the pancreas. A summary is shown for *Pax6* reporters lacking either L1 or L2 sites (21) or genetically deficient for Prep1 as assayed at E10.5. Only nucleotides that diverge from the wild-type EE sequence are shown. Lightly shaded L1 or L2 boxes indicate lower-affinity sites; white boxes indicate ablated binding sites. Binding site ablations for L1 and L2 are genetically indicated with Δ for deletion, although they are specific point mutations that have been tested by PBM and biochemical analyses to have no detectable Prep1 binding. Activity indicates relative β -galactosidase (name in blue) or GFP (name in green) reporter activity in the lens.

*L1*L2** transgenic embryos (Fig. 4; Supplemental Fig. 8), suggesting additional selective pressure against high-affinity Prep1 sites in the EE. These results provide a mechanistic link between Prep1-binding site affinity and the timing of *Pax6* expression during eye development.

Deciphering the *cis*-regulatory logic of enhancers governing the expression of developmental genes requires the description of coordinate action of multiple DNA-bound TFs. To what extent the role of individual sites can be dissected within the context of larger, complex vertebrate enhancers remains an open question. Here we describe a mammalian enhancer using binding site affinity of a single TF, Prep1, to regulate the temporal control of gene expression. Specifically, mutating the lower-affinity, native L1 and L2 Prep1 sites to higher-affinity sites resulted in high-level EE activity at an earlier developmental time point (Fig. 4D).

Coordination of the timing and level of *Pax6* expression is of particular importance because of the exquisite sensitivity of eye development to even subtle changes in *Pax6* levels; both *Pax6* heterozygotes (mouse) and *PAX6* hypomorphs (human) exhibit developmental phenotypes (Hill et al. 1991; Glaser et al. 1994; Schedl et al. 1996; van Raamsdonk and Tilghman 2000; Sansom et al.

2009). Lens development, particularly when the EE becomes active (E8.75), is highly sensitive to *Pax6* concentration, and a threshold model for *Pax6* function has been proposed (van Raamsdonk and Tilghman 2000). The lower affinities of L1 and L2 may have been evolutionarily selected to be most responsive to the developmental concentrations of Prep1 present when increasing levels of *Pax6* expression are required to coordinate lens morphogenesis. Other enhancers have been shown to contribute

Figure 4. L1 and L2 interact synergistically to activate the EE. (A) Summary and examples of *Pax6* reporter constructs with mutations in L1 or L2 sites that create high-affinity binding sites (asterisks and black boxes). The ratio indicates the number of transgenic embryos with lens β -galactosidase staining as a fraction of all transgenic embryos. Activity indicates relative β -galactosidase reporter activity in the lens. (B) Modeling of EE activation versus Prep1 concentration (log₂ scale) for *L1L2* modeled with synergy (black solid line) or without synergy (black dashed line), single-site mutations (Δ L1L2, *L1 Δ L2*, gray dashed line), or high-affinity site mutations (Δ L1L2*, *L1*L2*, gray solid line; *L1*L2**, blue solid line). (C) Ratio of activation levels for reporter constructs modeled in B to facilitate the comparison of model predictions and the ratio of relative reporter levels. Single high-affinity site mutations (*L1*L2*) versus wild-type (*L1L2*) reporter modeled with synergy (black line) or single-site ablation (*L1 Δ L2*, gray line); double high-affinity site mutation (*L1*L2**) versus wild-type (*L1L2*) reporter modeled with synergy (red line). We conservatively estimate the ratio differences between *L1* Δ L2* and *L1 Δ L2* to be at least twofold, between *L1L2* and *L1* Δ L2* to be at least fourfold, and between *L1*L2** and *L1L2* to be at most 1.3-fold. These estimates are based on β -galactosidase staining intensities and histochemical development times. The shaded area defines the predicted range of physiological concentration for Prep1. (D) β -Galactosidase staining of an eye from an E9.5 *L1*L2** transgenic embryo was more intense than from wild-type (*P0-3.9-L1L2*) embryos of increasingly older ages up to E10.25.

to *Pax6* lens expression both earlier and later than the EE (e.g., SIMO element) (Kleinjan et al. 2001), and may function coordinately with the EE to regulate *Pax6*. It is possible that *Prep1* may regulate *Pax6* expression via some of these other enhancers and possibly the P0 promoter (see Fig. 2C) in addition to the EE to account for the severe lens phenotype we observed in *Prep1*^{1/-} mice.

The quantitative measurement and modeling of binding site affinities has led to the development and testing of biophysical models of transcription (Wang et al. 1999; Bintu et al. 2005; Kim and O'Shea 2008; Segal et al. 2008; Gertz et al. 2009; Kim et al. 2009). Here we demonstrate that a biophysical model, parameterized with biochemical and in vivo reporter analyses, can describe the activity of the *Pax6* EE as a function of *Prep1* levels and binding site affinities. Additionally, our model provides a mechanism for decoupling the timing and levels of gene expression, whereby the affinities of the L1 and L2 sites for *Prep1* dictate when *Pax6* is expressed, while the level of activation is modulated by the synergistic activity of *Prep1* molecules noncooperatively bound to the two sites. The strict maintenance of the presence, affinity, and spacing of the L1 and L2 sites throughout the vertebrate lineage suggests evolutionary conservation of this regulatory mechanism.

Vast numbers of lower-affinity TF-binding sites are present in vertebrate genomes, but the functions of such sites remain unclear. Here we identified a functional role for lower-affinity TF-binding sites in establishing the temporal control of gene expression in the developing mouse. We propose that conservation of TF-binding sites as lower-affinity sites is a signature of CRMs that interpret temporal and/or spatial gradients of their upstream activators. Genomic searches for regulatory regions containing such conserved lower-affinity TF-binding sites (Jaeger et al. 2010) may identify other delicately calibrated enhancers controlling key developmental genes.

Materials and methods

Full descriptions of the Materials and Methods are available in the Supplemental Material.

Mouse genetics

P0-3.9-GFP^{Cre} mice were described previously, and were maintained as heterozygotes on an FVB background (Rowan et al. 2008). *Pax6*^{Sey-Neu} mice were maintained as heterozygotes on a C3H background. *Prep1*¹ (gift from Dr. Francesco Blasi) and *Prep1*⁻ (gift from Dr. Neal Copeland) mice were maintained as heterozygotes on a C57BL/6 background (Ferretti et al. 2006). Transgenic constructs were based on the pLNLKLS reporter plasmid containing the 526-bp *Pax6* EE directing *lacZ* expression (Zhang et al. 2002), except for the P0-3.9-L1ΔL2-*lacZ* reporter, which was based on the P0-3.9-*lacZ* reporter line (Zhang et al. 2006). Site-directed mutations were constructed using the QuikChange Lightning Site-Directed Mutagenesis Kit (Stratagene) according to the manufacturer's directions.

Tissue analyses

For antibody staining, primary antibodies used were mouse anti-*Pax6* (1:10; Development Studies Hybridoma Bank, The University of Iowa), rabbit anti-*Pax6* (1:1000; Covance Research Products), rabbit anti-Foxe3 (1:1000; gift from Dr. Peter Carlsson), goat anti-γ-crystallin (1:1000; Santa Cruz Biotechnologies), goat anti-Pdx1 (1:5000; gift from Dr. Chris Wright), guinea pig anti-*Prep1* (1:200) (Zhang et al. 2006), guinea pig anti-Six3 (1:500; Abcam), rabbit anti-Sox2 (1:1000; Chemicon), and goat anti-Meis1/2

(1:250; Santa Cruz Biotechnologies). Secondary antibodies were generated in donkey versus the appropriate species, and were directly conjugated with Cy3 (Jackson Immunologicals) or Alexa Fluor 488 (Molecular Probes).

Protein expression and SPR

GST-*Prep1* homeodomain and full-length ORFs (Berger et al. 2008) were expressed in *Escherichia coli*. Tagged protein was purified using GSTrap FF affinity columns (GE Healthcare) on an AKTA prime plus FPLC (GE Healthcare). Concentration of purified protein was determined by Coomassie Bradford assay. SPR was performed on a Biacore 3000. Biotinylated oligos were immobilized onto a Sensor Chip SA (Biacore). Serial concentrations of protein samples were diluted in running buffer and applied to the Sensor Chip at 25 μL/min, using the KINJECT option, 250-μL sample (1000-sec dissociation phase). Binding rate constants and equilibrium K_d values were determined using Scrubber2 software (BioLogic Software).

Computational analysis and modeling

The P0-3.9 region was searched for *Prep1* DNA-binding site sequences using custom Perl scripts (available on request). Eight-base-pair sequences were scored according to their PBM enrichment score, a statistical measure that ranges from -0.5 to +0.5 and indicates the binding preference of the protein, assayed in a universal PBM experiment, for a particular 8-mer as compared with all other 8-mers (Berger et al. 2008). *Prep1* PBM data are available via the UniPROBE database (Newburger and Bulyk 2009).

An equilibrium thermodynamic model, described recently by Bintu et al. (2005), was used to model transcriptional activation by the EE. Activation curves were modeled and visualized in Matlab. A full description of the model and parameterization method is in the Supplemental Materials.

Acknowledgments

We thank Francesco Blasi, Steve Gisselbrecht, Craig Kaplan, Daniel O'Connell, and Rolf Stottmann for critical comments on the manuscript, and members of the Maas and Bulyk laboratories for helpful discussion. We are especially grateful to Neal Copeland and Francesco Blasi for gifts of *Prep1* mutant mice. This work was supported by a fellowship from the Canadian Institutes of Health Research to S.R., NIH grant R01 HG003985 to M.L.B., and NIH grant R01 EY10123 to R.L.M.

References

- Aota S, Nakajima N, Sakamoto R, Watanabe S, Ibaraki N, Okazaki K. 2003. *Pax6* autoregulation mediated by direct interaction of *Pax6* protein with the head surface ectoderm-specific enhancer of the mouse *Pax6* gene. *Dev Biol* **257**: 1–13.
- Arnosti DN, Kulkarni MM. 2005. Transcriptional enhancers: Intelligent enhancosomes or flexible billboards? *J Cell Biochem* **94**: 890–898.
- Ashery-Padan R, Marquardt T, Zhou X, Gruss P. 2000. *Pax6* activity in the lens primordium is required for lens formation and for correct placement of a single retina in the eye. *Genes & Dev* **14**: 2701–2711.
- Berger MF, Badis G, Gehrke AR, Talukder S, Philippakis AA, Pena-Castillo L, Alleyne TM, Mnaimneh S, Botvinnik OB, Chan ET, et al. 2008. Variation in homeodomain DNA binding revealed by high-resolution analysis of sequence preferences. *Cell* **133**: 1266–1276.
- Bintu L, Buchler NE, Garcia HG, Gerland U, Hwa T, Kondev J, Phillips R. 2005. Transcriptional regulation by the numbers: Models. *Curr Opin Genet Dev* **15**: 116–124.
- Blixt A, Landgren H, Johansson BR, Carlsson P. 2007. Foxe3 is required for morphogenesis and differentiation of the anterior segment of the eye and is sensitive to *Pax6* gene dosage. *Dev Biol* **302**: 218–229.
- Davidson EH, Levine MS. 2008. Properties of developmental gene regulatory networks. *Proc Natl Acad Sci* **105**: 20063–20066.
- Davis-Silberman N, Kalich T, Oron-Karni V, Marquardt T, Kroeber M, Tamm ER, Ashery-Padan R. 2005. Genetic dissection of *Pax6* dosage requirements in the developing mouse eye. *Hum Mol Genet* **14**: 2265–2276.

- Dimanlig PV, Faber SC, Auerbach W, Makarenkova HP, Lang RA. 2001. The upstream ectoderm enhancer in Pax6 has an important role in lens induction. *Development* **128**: 4415–4424.
- Donner AL, Episkopou V, Maas RL. 2007. Sox2 and Pou2f1 interact to control lens and olfactory placode development. *Dev Biol* **303**: 784–799.
- Driever W, Thoma G, Nüsslein-Volhard C. 1989. Determination of spatial domains of zygotic gene expression in the *Drosophila* embryo by the affinity of binding sites for the bicoid morphogen. *Nature* **340**: 363–367.
- Duncan MK, Xie L, David LL, Robinson ML, Taube JR, Cui W, Reneker LW. 2004. Ectopic Pax6 expression disturbs lens fiber cell differentiation. *Invest Ophthalmol Vis Sci* **45**: 3589–3598.
- Ferretti E, Schulz H, Talarico D, Blasi F, Berthelsen J. 1999. The PBX-regulating protein PREP1 is present in different PBX-complexed forms in mouse. *Mech Dev* **83**: 53–64.
- Ferretti E, Villaescusa JC, Di Rosa P, Fernandez-Diaz LC, Longobardi E, Mazziere R, Miccio A, Micali N, Selli L, Ferrari G, et al. 2006. Hypomorphic mutation of the TALE gene Prep1 (pKnox1) causes a major reduction of Pbx and Meis proteins and a pleiotropic embryonic phenotype. *Mol Cell Biol* **26**: 5650–5662.
- Gaudet J, Mango SE. 2002. Regulation of organogenesis by the *Caenorhabditis elegans* FoxA protein PHA-4. *Science* **295**: 821–825.
- Gertz J, Siggia ED, Cohen BA. 2009. Analysis of combinatorial cis-regulation in synthetic and genomic promoters. *Nature* **457**: 215–218.
- Giorgetti L, Siggers T, Tiana G, Caprara G, Notarbartolo S, Corona T, Pasparakis M, Milani P, Bulyk ML, Natoli G. 2010. Noncooperative interactions between transcription factors and clustered DNA binding sites enable graded transcriptional responses to environmental inputs. *Mol Cell* **37**: 418–428.
- Glaser T, Jepeal L, Edwards JG, Young SR, Favor J, Maas RL. 1994. PAX6 gene dosage effect in a family with congenital cataracts, aniridia, anophthalmia and central nervous system defects. *Nat Genet* **7**: 463–471.
- Gordan R, Hartemink AJ, Bulyk ML. 2009. Distinguishing direct versus indirect transcription factor–DNA interactions. *Genome Res* **19**: 2090–2100.
- Gregor T, Tank DW, Wieschaus EF, Bialek W. 2007. Probing the limits to positional information. *Cell* **130**: 153–164.
- Grindley JC, Davidson DR, Hill RE. 1995. The role of Pax-6 in eye and nasal development. *Development* **121**: 1433–1442.
- Hill RE, Favor J, Hogan BLM, Ton CCT, Saunders GF, Hanson IM, Prosser J, Jordan T, Hastie ND, van Heyningen V. 1991. Mouse *Small eye* results from mutations in a paired-like homeobox-containing gene. *Nature* **354**: 522–525.
- Hollenhorst PC, Shah AA, Hopkins C, Graves BJ. 2007. Genome-wide analyses reveal properties of redundant and specific promoter occupancy within the ETS gene family. *Genes & Dev* **21**: 1882–1894.
- Jaeger SA, Chan ET, Berger MF, Stottmann R, Hughes TR, Bulyk ML. 2010. Conservation and regulatory associations of a wide affinity range of mouse transcription factor binding sites. *Genomics* **95**: 185–195.
- Jiang J, Levine M. 1993. Binding affinities and cooperative interactions with bHLH activators delimit threshold responses to the dorsal gradient morphogen. *Cell* **72**: 741–752.
- Kammandel B, Chowdhury K, Stoykova A, Aparicio S, Brenner S, Gruss P. 1999. Distinct cis-essential modules direct the time–space pattern of the Pax6 gene activity. *Dev Biol* **205**: 79–97.
- Kim H, O'Shea EK. 2008. A quantitative model of transcription factor-activated gene expression. *Nat Struct Mol Biol* **15**: 1192–1198.
- Kim HD, Shay T, O'Shea EK, Regev A. 2009. Transcriptional regulatory circuits: Predicting numbers from alphabets. *Science* **325**: 429–432.
- Kleinjan DA, Seawright A, Schedl A, Quinlan RA, Danes S, van Heyningen V. 2001. Aniridia-associated translocations, DNase hypersensitivity, sequence comparison and transgenic analysis redefine the functional domain of PAX6. *Hum Mol Genet* **10**: 2049–2059.
- Lai ZC, Maxson R, Childs G. 1988. Both basal and ontogenic promoter elements affect the timing and level of expression of a sea urchin H1 gene during early embryogenesis. *Genes & Dev* **2**: 173–183.
- Majka J, Speck C. 2007. Analysis of protein–DNA interactions using surface plasmon resonance. *Adv Biochem Eng Biotechnol* **104**: 13–36.
- Newburger D, Bulyk ML. 2009. UniPROBE: An online database of protein binding microarray data on protein–DNA interactions. *Nucleic Acids Res* **37**: D77–D82. doi: 10.1093/nar/gkn660.
- Rowan S, Conley KW, Le TT, Donner AL, Maas RL, Brown NL. 2008. Notch signaling regulates growth and differentiation in the mammalian lens. *Dev Biol* **321**: 111–122.
- Sansom SN, Griffiths DS, Faedo A, Kleinjan DJ, Ruan Y, Smith J, van Heyningen V, Rubenstein JL, Livesey FJ. 2009. The level of the transcription factor Pax6 is essential for controlling the balance between neural stem cell self-renewal and neurogenesis. *PLoS Genet* **5**: e1000511. doi: 10.1371/journal.pgen.1000511.
- Scardigli R, Baumer N, Gruss P, Guillemot F, Le Roux I. 2003. Direct and concentration-dependent regulation of the proneural gene Neurogenin2 by Pax6. *Development* **130**: 3269–3281.
- Schedl A, Ross A, Lee M, Engelkamp D, Rashbass P, van Heyningen V, Hastie ND. 1996. Influence of PAX6 gene dosage on development: Overexpression causes severe eye abnormalities. *Cell* **86**: 71–82.
- Segal E, Ravich-Sadka T, Schroeder M, Unnerstall U, Gaul U. 2008. Predicting expression patterns from regulatory sequence in *Drosophila* segmentation. *Nature* **451**: 535–540.
- Struhl G, Struhl K, Macdonald PM. 1989. The gradient morphogen bicoid is a concentration-dependent transcriptional activator. *Cell* **57**: 1259–1273.
- van Raamsdonk CD, Tilghman SM. 2000. Dosage requirement and allelic expression of PAX6 during lens placode formation. *Development* **127**: 5439–5448.
- Wang J, Ellwood K, Lehman A, Carey MF, She ZS. 1999. A mathematical model for synergistic eukaryotic gene activation. *J Mol Biol* **286**: 315–325.
- Williams SC, Altmann CR, Chow RL, Hemmati-Brivanlou A, Lang RA. 1998. A highly conserved lens transcriptional control element from the Pax-6 gene. *Mech Dev* **73**: 225–229.
- Yuh CH, Bolouri H, Davidson EH. 1998. Genomic cis-regulatory logic: Experimental and computational analysis of a sea urchin gene. *Science* **279**: 1896–1902.
- Zhang X, Friedman A, Heaney S, Purcell P, Maas RL. 2002. Meis homeoproteins directly regulate Pax6 during vertebrate lens morphogenesis. *Genes & Dev* **16**: 2097–2107.
- Zhang X, Rowan S, Yue Y, Heaney S, Pan Y, Brendolan A, Selli L, Maas RL. 2006. Pax6 is regulated by Meis and Pbx homeoproteins during pancreatic development. *Dev Biol* **300**: 748–757.

Precise temporal control of the eye regulatory gene *Pax6* via enhancer-binding site affinity

Sheldon Rowan, Trevor Siggers, Salil A. Lachke, et al.

Genes Dev. 2010, **24**: originally published online April 22, 2010
Access the most recent version at doi:[10.1101/gad.1890410](https://doi.org/10.1101/gad.1890410)

Supplemental Material

<http://genesdev.cshlp.org/content/suppl/2010/04/14/gad.1890410.DC1>

References

This article cites 44 articles, 15 of which can be accessed free at:
<http://genesdev.cshlp.org/content/24/10/980.full.html#ref-list-1>

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).